| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 5046- | erastin, | SAS, | The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis |
| - | Study, | Var, | NA |
| 6585- | EU, | Anti-Tumor Activity of Eurycoma longifolia Root Extracts against K-562 Cell Line: In Vitro and In Vivo Study |
| - | vitro+vivo, | AML, | K562 |
| 6384- | Eug, | Eugenol modulates the NOD1-NF-κB signaling pathway via targeting NF-κB protein in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-453 |
| 6355- | Eug, | Pharmacological and Toxicological Properties of Eugenol |
| - | Review, | Var, | NA |
| 6377- | Eug, | Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 6339- | Eug, | Induction of apoptosis by eugenol in human breast cancer cells |
| - | in-vitro, | BC, | NA |
| 6845- | EVO, | Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6846- | EVO, | Evodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 |
| 6843- | EVO, | Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells |
| - | in-vivo, | PC, | PANC1 | - | in-vitro, | PC, | SW1990 |
| 1022- | EVO, | Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis |
| - | in-vivo, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 |
| 6853- | FBZ, | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 6855- | FBZ, | Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study |
| - | vitro+vivo, | Ovarian, | A2780S | - | vitro+vivo, | Ovarian, | SKOV3 |
| 2496- | FBZ, | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 6427- | FEO, | Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | NA |
| 6891- | Fer, | Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma |
| - | vitro+vivo, | lymphoma, | NA |
| 6890- | Fer, | Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues |
| - | vitro+vivo, | Var, | NA |
| 6897- | FIS, | Fisetin: A Dietary Antioxidant for Health Promotion |
| - | Review, | Nor, | NA |
| 6906- | FIS, | Rad, | Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models |
| - | in-vivo, | CRC, | CT26 | - | in-vivo, | CRC, | HCT116 |
| 6901- | FIS, | Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC |
| - | in-vivo, | HNSCC, | CAL33 |
| 6898- | FIS, | Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 6994- | FIS, | Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells |
| - | in-vitro, | Colon, | HT29 |
| 2859- | FIS, | The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways |
| - | in-vitro, | Liver, | HepG2 | - | NA, | Colon, | Caco-2 |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2831- | FIS, | Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6984- | Form, | Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling |
| - | in-vitro, | Colon, | HCT116 | - | Review, | IBD, | RAW264.7 |
| 6987- | Form, | Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p |
| - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | BC, | MGC803 |
| 6993- | Form, | ISL, | Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell |
| - | in-vitro, | CRC, | HCT116 |
| 6976- | Form, | Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle |
| - | vitro+vivo, | HCC, | HepG2 |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
| 6972- | Form, | PacT, | Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy |
| - | in-vivo, | BC, | MDA-MB-231 |
| 8313- | FS, | Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? |
| - | Review, | BC, | NA |
| 8584- | FS, | Anti-Oxidant and Anti-Cancer Properties of Flaxseed |
| - | Review, | Nor, | NA |
| 8590- | FS, | The Effect of Flaxseed in Breast Cancer: A Literature Review |
| - | Review, | BC, | NA |
| 8596- | FSO, | Treatment with flaxseed oil induces apoptosis in cultured malignant cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Melanoma, | B16-BL6 |
| 7022- | Fuc, | Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling |
| - | in-vitro, | Colon, | HT29 |
| 7007- | Fuc, | The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles |
| - | Review, | Var, | NA |
| 948- | Fuc, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 4024- | FulvicA, | ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES |
| - | Review, | Var, | NA |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 7043- | GA, | Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase |
| - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | A549 |
| 7029- | GA, | Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | MCF10 |
| 987- | GA, | Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug |
| - | in-vitro, | GBM, | AMGM | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF7 |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 5207- | Gallo, | Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism |
| - | in-vitro, | PC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid